Latest Cellular Biomedicine Group Inc. (CBMG) Head
Post# of 58
Posted On: 03/09/2014 6:02:12 AM
Latest Cellular Biomedicine Group Inc. (CBMG) Headlines
Cellular Biomedicine Group Announces Updated Results From Phase I/IIa Clinical Trial for ReJoin(TM) Treatment of Knee Osteoarthritis (KOA)
GlobeNewswire - Mon Feb 24, 10:15AM CST
Cellular Biomedicine Group, Inc. (OTCQB:CBMG) today announced updated analysis of its Phase I/IIa clinical trial for human adipose-derived mesenchymal precursor cell (haMPC) therapy for Knee Osteoarthritis (KOA), which tests the safety and efficacy of intra-articular injections of autologous haMPCs in order to reduce inflammation and repair damaged joint cartilage. Completed in Q4 2013, the data shows no serious adverse events (SAE), suggesting ReJoin cell therapy for KOA patients is safe.
Cellular Biomedicine Group to Present at New York Stem Cell Summit
GlobeNewswire - Wed Feb 05, 6:24PM CST
Cellular Biomedicine Group Inc. (OTCQB:CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced that Dr. Wei (William) Cao, Chief Executive Officer, will be presenting at the 9th annual New York Stem Cell Summit. More than 30 of the world's leaders in this rapidly evolving industry will meet on February 18, 2014 at The Convene in New York City to discuss the global stem cell industry outlook and forecast.
Cellular Biomedicine Group Announces Appointment of New Chief Financial Officer and Board Secretary and New Audit Committee Chair
GlobeNewswire - Fri Jan 03, 11:45AM CST
Cellular Biomedicine Group Inc. (OTCQB:CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced the appointment of Bizuo (Tony) Liu as Chief Financial Officer and Board Secretary and the election of Nadir Patel as Independent Director, Chairman of the Audit Committee of the board of directors of CBMG.
Cellular Biomedicine Group Announces Completion of Patient Treatment for Phase I Clinical Trial for Liver Cancer
PR Newswire - Fri Dec 13, 2:33PM CST
Cellular Biomedicine Group, Inc. (OTCQB: CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, is pleased to announce that it has treated the final patient of its Phase I clinical trial which evaluates the safety and preliminary efficacy of TC-DC (Tumor Stem Cell Specific Dendritic Cell) therapy for hepatocellular carcinoma (HCC), the most common type of liver cancer.
Cellular Biomedicine Group to Present "Expedited Development of Cellular Medicine" at Hong Kong Biotech Horizons Conference
GlobeNewswire - Tue Nov 19, 12:05AM CST
Cellular Biomedicine Group, Inc. (OTCQB:CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced that Wei (William) Cao, Ph.D., B.M., Chief Executive Officer, will present at the Hong Kong Biotech Horizons Conference on Thursday, November 21, 2013, at 11:15 a.m. at the Charles K. Kao Auditorium, Hong Kong Science and Technology Park, Hong Kong.
Cellular Biomedicine Group Announces Adjournment of Its Annual Shareholder Meeting
PR Newswire - Sat Nov 09, 4:55AM CST
Cellular Biomedicine Group, Inc. (OTCQB: CBMG) today convened the annual meeting of its shareholders. Because a quorum was not achieved by shares present at the meeting in person or by proxy, the shareholder meeting was adjourned to a later date as to be determined by the board of directors of the Company. The board of directors has fixed the close of business on November 18, 2013 as the record date for the determination of stockholders entitled to notice of and to vote at the annual meeting. New proxy materials will be distributed to all the shareholders. Management of the Company is confident that a quorum will be achieved in the re-convened meeting.
Cellular Biomedicine Group Announces November 07, 2013 as Voting Deadline for Its Annual Shareholder Meeting
PR Newswire - Thu Nov 07, 1:45PM CST
Cellular Biomedicine Group, Inc. (OTCQB: CBMG) today reminded all its shareholders that the Board of the Company has set November 08, 2013 as the date for the Company's annual meeting of stockholders, to be held at 530 University Ave, Suite 17, Palo Alto, CA 94301, at 9:00am PST, and any and all adjournments or postponements thereof, and authorizes and instructs the mailed proxies to vote in the manner directed in each proxy card for each shareholder of record.
Cellular Biomedicine Group Receives Approval for Phase IIb Clinical Trial of ReJoin(TM) for Treatment of Knee Osteoarthritis (KOA)
PR Newswire - Tue Nov 05, 10:36AM CST
Cellular Biomedicine Group, Inc. (OTCQB: CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced that it has received approval to conduct a Phase IIb clinical trial for ReJoin(TM), a human adipose-derived mesenchymal precursor cells (haMPC) therapy bio-engineered for Knee Osteoarthritis (KOA). The trial tests the safety and efficacy of intra-articular injections of autologous (patient's own) ReJoin(TM) formula in order to reduce inflammation and repair damaged joint cartilage.
Cellular Biomedicine Group Announces Completion of Patient Treatment for Phase I/IIa Clinical Trial for Treatment of Knee Osteoarthritis (KOA)
PR Newswire - Fri Nov 01, 9:01AM CDT
Cellular Biomedicine Group, Inc. (OTCQB: CBMG) is pleased to announce that it has treated the final patient of its Phase I/IIa clinical trial for ReJoin(TM), a human adipose-derived mesenchymal precursor cell (haMPC) therapy for Knee Osteoarthritis (KOA). The trial tests the safety and efficacy of intra-articular injections of autologous (patient's own) haMPCs in order to reduce inflammation and repair damaged joint cartilage.
Cellular Biomedicine Group Announces New Product Approved for Market in China and New Exclusive License
PR Newswire - Wed Oct 30, 8:01AM CDT
Today Cellular Biomedicine Group (OTCQB:CBMG) announced that their A-Stromal(TM) adipose stromal cell purification kit is ready to launch on the market in China. In addition, they have signed an exclusive China and Hong Long license for ProCeller computer controlled processing system to extract stem cells from adipose tissue. These two products, when used together, allow for safe and contaminant-free isolation of one million Vascular Stromal Cells per 1 mL of adipose tissue in as little as sixty minutes. The potential clients for both products are cosmetic clinics, research institutions, sports medicine departments and veterinarian clinics.
Cellular Biomedicine Group calls for General Annual Shareholder Meeting on November 08, 2013
PR Newswire - Fri Oct 25, 9:08AM CDT
Cellular Biomedicine Group, Inc. (OTCQB:CBMG) today announced that the Board of the Company has set November 08, 2013 as the date for the Company's annual meeting of stockholders, to be held at 530 University Ave, Suite 17, Palo Alto, CA 94301, at 9:00am PST, and any and all adjournments or postponements thereof, and authorizes and instructs the mailed proxies to vote in the manner directed in each proxy card for each shareholder of record.
Cellular Biomedicine Group Appoints Three Independent Directors to the Board
PR Newswire - Mon Oct 14, 8:44AM CDT
Cellular Biomedicine Group, Inc. (OTCQB: CBMG) today announced that the Board of the Company has appointed three new independent directors to the Board, namely, Leo Dembinski, David Bolocan and Jeff Auerbach.
Cellular Biomedicine Group Announces Change of Auditor
PR Newswire - Wed Sep 11, 8:28AM CDT
Cellular Biomedicine Group, Inc. (OTCQB: CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced that the Company has engaged BDO USA, LLP ("BDO") as its independent registered public accounting firm, replacing Tarvaran Askelon & Company ("TAC").
Cellular Biomedicine Group Announces Positive Interim Results from Phase I/IIa Clinical Trial for Treatment of Knee Osteoarthritis (KOA)
PR Newswire - Fri Sep 06, 6:00AM CDT
Cellular Biomedicine Group, Inc. (OTCQB: CBMG) today announced the interim results of its Phase I/IIa clinical trial for human adipose-derived mesenchymal precursor cell (haMPC) therapy for Knee Osteoarthritis (KOA), which tests the safety and efficacy of intra-articular injections of autologous (patient's own) haMPCs in order to reduce inflammation and repair damaged joint cartilage. On schedule for completion in Q4 2013, the interim analysis of the trial has preliminarily demonstrated a significant improvement (P<0.05) from the baseline in clinical scores for SF-36, NRS-11, and WOMAC osteoarthritis indices, and no serious adverse events have been reported.
Cellular Biomedicine Group Announces Completion of Patient Enrollment for Phase I Clinical Trial for Liver Cancer
PR Newswire - Thu Aug 22, 10:48AM CDT
Cellular Biomedicine Group (OTCQB: CBMG) today announced that it has completed patient enrollment for its Phase I trial to evaluate the safety and preliminary efficacy of TC-DC (Tumor Stem Cell Specific Dendritic Cell) therapy for hepatocellular carcinoma (HCC), the most common type of liver cancer.
Cellular Biomedicine Group Reports Second Quarter and First Half 2013 Financial Results and Business Highlights
PR Newswire - Fri Aug 16, 10:17AM CDT
Cellular Biomedicine Group, Inc. (OTCQB: CBMG), a developer of proprietary cell therapies for the treatment of degenerative diseases and cancers, this week reported financial results and business highlights for the quarter and six months ended June 30, 2013.
CRWEPRESSRELEASE Daily Stock Watch Harris & Harris Group, Inc., (NASDAQ:TINY), Crown Equity Holdings Inc. (OTCQB:CRWE), and Cellular Biomedicine Group (OTCQB:CBMG)
WorldStockWire - Tue Jul 30, 11:00AM CDT
CRWEpressrelease.com, a division of Crown Equity Holdings Inc. (OTCQB:CRWE) tracks stocks daily and is pleased to offer its hot stock to watch . Our stock focus today is on:
Cellular Biomedicine Group Completes Enrollment in Phase I Clinical Trial for Knee Osteoarthritis
PR Newswire - Mon Jul 22, 9:25AM CDT
Cellular Biomedicine Group (OTCQB:CBMG) today announced that it has completed the enrollment required for its Phase I trial to evaluate the safety and preliminary efficacy of the medical technology haMPC (Human Adipose-derived Mesenchymal Progenitor Cells) therapy for Knee Osteoarthritis (KOA).
STOCKBLIZZARD Daily Stock Watch Crown Equity Holdings, Inc. (OTCQB:CRWE), AutoChina International Limited (OTCQB:LDHL), and Cellular Biomedicine Group, Inc. (OTCQB:CBMG)
WorldStockWire - Mon Jul 15, 7:00PM CDT
Stockblizzard.com, a division of Crown Equity Holdings Inc. (OTCQB:CRWE) tracks stocks daily and is pleased to offer its hot stock to watch . Our stock focus today is on:
Cellular Biomedicine Group Appoints Director of Medical Research
PR Newswire - Thu Jul 11, 1:39PM CDT
Cellular Biomedicine Group, Inc. (OTCQB: CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced the appointment of Maxwell Wang, M.D., PhD, as Director of Medical Research.
Cellular Biomedicine Group Announces Updated Results From Phase I/IIa Clinical Trial for ReJoin(TM) Treatment of Knee Osteoarthritis (KOA)
GlobeNewswire - Mon Feb 24, 10:15AM CST
Cellular Biomedicine Group, Inc. (OTCQB:CBMG) today announced updated analysis of its Phase I/IIa clinical trial for human adipose-derived mesenchymal precursor cell (haMPC) therapy for Knee Osteoarthritis (KOA), which tests the safety and efficacy of intra-articular injections of autologous haMPCs in order to reduce inflammation and repair damaged joint cartilage. Completed in Q4 2013, the data shows no serious adverse events (SAE), suggesting ReJoin cell therapy for KOA patients is safe.
Cellular Biomedicine Group to Present at New York Stem Cell Summit
GlobeNewswire - Wed Feb 05, 6:24PM CST
Cellular Biomedicine Group Inc. (OTCQB:CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced that Dr. Wei (William) Cao, Chief Executive Officer, will be presenting at the 9th annual New York Stem Cell Summit. More than 30 of the world's leaders in this rapidly evolving industry will meet on February 18, 2014 at The Convene in New York City to discuss the global stem cell industry outlook and forecast.
Cellular Biomedicine Group Announces Appointment of New Chief Financial Officer and Board Secretary and New Audit Committee Chair
GlobeNewswire - Fri Jan 03, 11:45AM CST
Cellular Biomedicine Group Inc. (OTCQB:CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced the appointment of Bizuo (Tony) Liu as Chief Financial Officer and Board Secretary and the election of Nadir Patel as Independent Director, Chairman of the Audit Committee of the board of directors of CBMG.
Cellular Biomedicine Group Announces Completion of Patient Treatment for Phase I Clinical Trial for Liver Cancer
PR Newswire - Fri Dec 13, 2:33PM CST
Cellular Biomedicine Group, Inc. (OTCQB: CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, is pleased to announce that it has treated the final patient of its Phase I clinical trial which evaluates the safety and preliminary efficacy of TC-DC (Tumor Stem Cell Specific Dendritic Cell) therapy for hepatocellular carcinoma (HCC), the most common type of liver cancer.
Cellular Biomedicine Group to Present "Expedited Development of Cellular Medicine" at Hong Kong Biotech Horizons Conference
GlobeNewswire - Tue Nov 19, 12:05AM CST
Cellular Biomedicine Group, Inc. (OTCQB:CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced that Wei (William) Cao, Ph.D., B.M., Chief Executive Officer, will present at the Hong Kong Biotech Horizons Conference on Thursday, November 21, 2013, at 11:15 a.m. at the Charles K. Kao Auditorium, Hong Kong Science and Technology Park, Hong Kong.
Cellular Biomedicine Group Announces Adjournment of Its Annual Shareholder Meeting
PR Newswire - Sat Nov 09, 4:55AM CST
Cellular Biomedicine Group, Inc. (OTCQB: CBMG) today convened the annual meeting of its shareholders. Because a quorum was not achieved by shares present at the meeting in person or by proxy, the shareholder meeting was adjourned to a later date as to be determined by the board of directors of the Company. The board of directors has fixed the close of business on November 18, 2013 as the record date for the determination of stockholders entitled to notice of and to vote at the annual meeting. New proxy materials will be distributed to all the shareholders. Management of the Company is confident that a quorum will be achieved in the re-convened meeting.
Cellular Biomedicine Group Announces November 07, 2013 as Voting Deadline for Its Annual Shareholder Meeting
PR Newswire - Thu Nov 07, 1:45PM CST
Cellular Biomedicine Group, Inc. (OTCQB: CBMG) today reminded all its shareholders that the Board of the Company has set November 08, 2013 as the date for the Company's annual meeting of stockholders, to be held at 530 University Ave, Suite 17, Palo Alto, CA 94301, at 9:00am PST, and any and all adjournments or postponements thereof, and authorizes and instructs the mailed proxies to vote in the manner directed in each proxy card for each shareholder of record.
Cellular Biomedicine Group Receives Approval for Phase IIb Clinical Trial of ReJoin(TM) for Treatment of Knee Osteoarthritis (KOA)
PR Newswire - Tue Nov 05, 10:36AM CST
Cellular Biomedicine Group, Inc. (OTCQB: CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced that it has received approval to conduct a Phase IIb clinical trial for ReJoin(TM), a human adipose-derived mesenchymal precursor cells (haMPC) therapy bio-engineered for Knee Osteoarthritis (KOA). The trial tests the safety and efficacy of intra-articular injections of autologous (patient's own) ReJoin(TM) formula in order to reduce inflammation and repair damaged joint cartilage.
Cellular Biomedicine Group Announces Completion of Patient Treatment for Phase I/IIa Clinical Trial for Treatment of Knee Osteoarthritis (KOA)
PR Newswire - Fri Nov 01, 9:01AM CDT
Cellular Biomedicine Group, Inc. (OTCQB: CBMG) is pleased to announce that it has treated the final patient of its Phase I/IIa clinical trial for ReJoin(TM), a human adipose-derived mesenchymal precursor cell (haMPC) therapy for Knee Osteoarthritis (KOA). The trial tests the safety and efficacy of intra-articular injections of autologous (patient's own) haMPCs in order to reduce inflammation and repair damaged joint cartilage.
Cellular Biomedicine Group Announces New Product Approved for Market in China and New Exclusive License
PR Newswire - Wed Oct 30, 8:01AM CDT
Today Cellular Biomedicine Group (OTCQB:CBMG) announced that their A-Stromal(TM) adipose stromal cell purification kit is ready to launch on the market in China. In addition, they have signed an exclusive China and Hong Long license for ProCeller computer controlled processing system to extract stem cells from adipose tissue. These two products, when used together, allow for safe and contaminant-free isolation of one million Vascular Stromal Cells per 1 mL of adipose tissue in as little as sixty minutes. The potential clients for both products are cosmetic clinics, research institutions, sports medicine departments and veterinarian clinics.
Cellular Biomedicine Group calls for General Annual Shareholder Meeting on November 08, 2013
PR Newswire - Fri Oct 25, 9:08AM CDT
Cellular Biomedicine Group, Inc. (OTCQB:CBMG) today announced that the Board of the Company has set November 08, 2013 as the date for the Company's annual meeting of stockholders, to be held at 530 University Ave, Suite 17, Palo Alto, CA 94301, at 9:00am PST, and any and all adjournments or postponements thereof, and authorizes and instructs the mailed proxies to vote in the manner directed in each proxy card for each shareholder of record.
Cellular Biomedicine Group Appoints Three Independent Directors to the Board
PR Newswire - Mon Oct 14, 8:44AM CDT
Cellular Biomedicine Group, Inc. (OTCQB: CBMG) today announced that the Board of the Company has appointed three new independent directors to the Board, namely, Leo Dembinski, David Bolocan and Jeff Auerbach.
Cellular Biomedicine Group Announces Change of Auditor
PR Newswire - Wed Sep 11, 8:28AM CDT
Cellular Biomedicine Group, Inc. (OTCQB: CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced that the Company has engaged BDO USA, LLP ("BDO") as its independent registered public accounting firm, replacing Tarvaran Askelon & Company ("TAC").
Cellular Biomedicine Group Announces Positive Interim Results from Phase I/IIa Clinical Trial for Treatment of Knee Osteoarthritis (KOA)
PR Newswire - Fri Sep 06, 6:00AM CDT
Cellular Biomedicine Group, Inc. (OTCQB: CBMG) today announced the interim results of its Phase I/IIa clinical trial for human adipose-derived mesenchymal precursor cell (haMPC) therapy for Knee Osteoarthritis (KOA), which tests the safety and efficacy of intra-articular injections of autologous (patient's own) haMPCs in order to reduce inflammation and repair damaged joint cartilage. On schedule for completion in Q4 2013, the interim analysis of the trial has preliminarily demonstrated a significant improvement (P<0.05) from the baseline in clinical scores for SF-36, NRS-11, and WOMAC osteoarthritis indices, and no serious adverse events have been reported.
Cellular Biomedicine Group Announces Completion of Patient Enrollment for Phase I Clinical Trial for Liver Cancer
PR Newswire - Thu Aug 22, 10:48AM CDT
Cellular Biomedicine Group (OTCQB: CBMG) today announced that it has completed patient enrollment for its Phase I trial to evaluate the safety and preliminary efficacy of TC-DC (Tumor Stem Cell Specific Dendritic Cell) therapy for hepatocellular carcinoma (HCC), the most common type of liver cancer.
Cellular Biomedicine Group Reports Second Quarter and First Half 2013 Financial Results and Business Highlights
PR Newswire - Fri Aug 16, 10:17AM CDT
Cellular Biomedicine Group, Inc. (OTCQB: CBMG), a developer of proprietary cell therapies for the treatment of degenerative diseases and cancers, this week reported financial results and business highlights for the quarter and six months ended June 30, 2013.
CRWEPRESSRELEASE Daily Stock Watch Harris & Harris Group, Inc., (NASDAQ:TINY), Crown Equity Holdings Inc. (OTCQB:CRWE), and Cellular Biomedicine Group (OTCQB:CBMG)
WorldStockWire - Tue Jul 30, 11:00AM CDT
CRWEpressrelease.com, a division of Crown Equity Holdings Inc. (OTCQB:CRWE) tracks stocks daily and is pleased to offer its hot stock to watch . Our stock focus today is on:
Cellular Biomedicine Group Completes Enrollment in Phase I Clinical Trial for Knee Osteoarthritis
PR Newswire - Mon Jul 22, 9:25AM CDT
Cellular Biomedicine Group (OTCQB:CBMG) today announced that it has completed the enrollment required for its Phase I trial to evaluate the safety and preliminary efficacy of the medical technology haMPC (Human Adipose-derived Mesenchymal Progenitor Cells) therapy for Knee Osteoarthritis (KOA).
STOCKBLIZZARD Daily Stock Watch Crown Equity Holdings, Inc. (OTCQB:CRWE), AutoChina International Limited (OTCQB:LDHL), and Cellular Biomedicine Group, Inc. (OTCQB:CBMG)
WorldStockWire - Mon Jul 15, 7:00PM CDT
Stockblizzard.com, a division of Crown Equity Holdings Inc. (OTCQB:CRWE) tracks stocks daily and is pleased to offer its hot stock to watch . Our stock focus today is on:
Cellular Biomedicine Group Appoints Director of Medical Research
PR Newswire - Thu Jul 11, 1:39PM CDT
Cellular Biomedicine Group, Inc. (OTCQB: CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced the appointment of Maxwell Wang, M.D., PhD, as Director of Medical Research.
(0)
(0)